UI announced in an email Thursday that the UI medical school was decided as part of the complex clinical trial of the AZD1222 vaccine, one of only 4 COVID-19 vaccines in Phase III.
Scientists at the University of Oxford began developing the AZD1222 vaccine in January, and the first findings appeared that the vaccine produces T cells and antibodies, according to the email.sites across the country, as email says
The Phase III path is the last step required before the Food and Drug Administration can pass the possible vaccine and will have a total of 30,000 participants in the United States, according to the email.
It will be located in the clinical studies center of IU Health University Hospital and is the only checkArray in Indiana according to email.
The email indicates that you will be directed through dr.Cynthia Brown, Associate Professor of Clinical Medicine at the U.S. School of Medicine.
Once open, Brown plans to enroll up to 1,500 volunteers within 8 weeks, according to email.
Volunteer participants will be the demographics of the Indianapolis population, and Brown noted that nearly 40% of the city’s population is black, Hispanic or Asian, so it is vital to have as many backgrounds as you can imagine in the trial, according to the email.
Volunteer participants must be 18 years of age or older and should not have had a positive diagnosis of COVID-19, but must have a greater threat of contracting the virus, such as those found in schools, shops, warehouses.or within the physical care system, according to email.
Volunteers from across the state are encouraged to participate and will be compensated, but will have to go to Indianapolis to receive two doses of the vaccine or placebo in addition to follow-up visits.
UI has the infrastructure to effectively manage s, Tatiana Foroud, associate dean of study affairs at the U.S. School of Medicine, said in the email.
Do you like what you read? Support independent and award-winning educational journalism on this site.Donate here.
Receive email updates with weekly headlines and summaries.
Subscribe to: